Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZFAND6 | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
mRNA | TMEM145 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | SYP | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | CBFA2T2 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
mRNA | KAT6A | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
mRNA | UNC5A | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
mRNA | N4BP2L1 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
mRNA | C21orf58 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
mRNA | SSFA2 | CTRPv2 | pan-cancer | AAC | -0.15 | 1e-05 |
mRNA | RP11-722G7.1 | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |